secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001558370-23-004017
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata reports Q4 2022 loss of $10.3M; positive phage trial data, $30M financing closed
--------------------------------------------------------------------------------

- R&D expenses $9.6M in Q4 2022, up from $4.8M in Q4 2021, driven by clinical trial investment.
- Cash $14.9M at Dec 31, 2022; closed $30M convertible credit with Innoviva in Q4.
- Positive topline results from SWARM-P.a. Phase 1b/2a for AP-PA02 in CF patients; advancing to Phase 2b.
- First patient dosed in Phase 2 NCFB study for AP-PA02; AP-SA02 bacteremia study first cohort completed.
- Loss from operations $(10.3)M vs $(6.0)M in Q4 2021; grant revenue $1.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/armp-20230316x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer